Jeanie Magdalena Gatewood’s Post

View profile for Jeanie Magdalena Gatewood, graphic

Clinical Research Solutions Strategist | Doctoral Researcher

Leading the way in collaborative compounds, drug discovery and targeted therapeutics - what a joy to share that the joint effort of Moderna & Carisma Therapeutics has yielded the first in a series of candidates. This nomination leverages mRNA-based in vivo CAR-M to develop a novel cell therapy targeting GPC3 in solid tumors - and which is known to be highly expressed in hepatocellular carcinoma. "HCC is the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S." Let's bring forward some new options for patients! #HCC #LiverCancer #PatientPotential #mRNA #Macrophage #Monocyte #GPC3 #Glypican3 #collaboration #drugdiscovery #targetedtherapeutics #celltherapy #celliconvalley #immunotherapy #solidtumor #NasdaqCARM

View organization page for Carisma Therapeutics, graphic

14,457 followers

We are excited to announce the nomination of the first Development Candidate under our collaboration with Moderna, Inc. The Development Candidate is an in vivo CAR-M targeting Glypican-3 and is designed to treat solid tumors, including hepatocellular carcinoma, the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S. Read more in the press release here: https://lnkd.in/gpeaEx_v #Immunotherapy #CancerResearch #SolidTumors #LiverCancer #HCC

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics